Abstract
Objectives Prognostic significance of stromal tumor infiltrating lymphocytes (sTILs) is evaluated to identify a responsive subset of TNBC in an Indian cohort of breast cancer patients.
Methods A retrospective cohort of breast cancer patients from a single onco-surgeon breast cancer clinic treated with uniform treatment strategy across is evaluated for sTILs. FFPE tissue of primary tumor of invasive breast carcinoma are collected with ethical approvals. Tumor sections blinded for subtypes are stained with H&E and scored for sTILs by a pathologist following Immuno-Oncology TILs working group’s scoring guidelines.
Results Analysis of 144 primary breast tumors for sTILs scores re-enforces significantly higher infiltration in TNBC tumors than HER2+ and ER+ tumors. Higher sTILs scores co-relate with gradually incremental pathological response to therapy specifically in TNBC subset and with better disease-free survival outcomes. Within TNBC, older and post-menopausal patients harbor higher scores of sTILs.
Conclusion Despite a small cohort of breast cancer patients, TNBC subtype reflected significantly higher scores of sTILs with better response to therapy and disease-free outcomes as compared to other breast cancer subtypes. A larger number of breast cancer patients from an Indian cohort will strengthen the findings to establish sTILs as a marker to identify a responsive subset of TNBC.
Key point 1 This is a first attempt to understand the significance of stromal tumor-infiltrating lymphocytes in a breast cancer cohort from India, where higher recurrence and mortality rates are observed.
Key point 2 TNBC tumors show higher sTILs infiltration compared to non-TNBC patients. Higher sTILs scores within TNBC co-relates with better therapy response disease-free survival.
Key point 3 Higher sTILs scores in TNBC tumors in an Indian cohort showed a novel and unique association with old age and post-menopausal patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MK would like to acknowledge DBT- Ramalingaswami re-entry fellowship awarded by DBT-India. LSS would like to acknowledge DST-JC Bose Research Fellowship. Research grant to CTCR is supported by Bajaj Auto Ltd. PV would like to acknowledge Aditi Khatpe, Rutvi Shah and Dimple Adiwal for their help in standardization.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Ethics Committee with DCGI/CDSCO Registration Number : ECR/298/Indt/MH/2018 (dated 14/May/2018) accredited by Drugs Controller General of India
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest statement: The authors declare no conflict of interest
Data Availability
All the data is presented here in the manuscript. Further details can be provided upon request.
